March 9, 2026
Although never give up the tick, investors should tiptoe in, given the dearth of February and March’s losses for possible set-ups
We are all observers on this geo-political “event,” at NO time be out-of-sight
Pre-Open Signals: 4 Negative and 2 Positive Indications
Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.
Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!
March 8, 2026
14.9 M shares priced at $5.61 with a positive +$0.15 or +2.22% Monday pre-open
Oversubscribed, 3/6/26
The private placement was anchored by existing and new investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others.
March 8, 2026
Equities were disappointing econ by the latest jobs data
News: Vinay Prasad, the head of the US FDA’s division of vaccines and gene therapies is leaving the agency after a tumultuous tenure. Dr. Prasad will depart the Center for Biologics Evaluation and Research next month to return to his prior career in academia. Prasad sparked controversy for overruling his own scientific review staff at times and taking a confrontational approach that critics said would stymie scientific innovation and slow approvals for rare disease drugs.
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision
Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!
It’s a Sunday update following Friday’s sick call
March 8, 2026
14.9 M shares priced at $5.61 with a positive +$0.15 or +2.22% Monday pre-open Oversubscribed, 3/6/26 The private placement was anchored by existing and new investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others.
February 15, 2026
A scorecard of covered companies Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status" I have written what I as an investor would want to know … Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
February 4, 2026
SGMO continues to fall -$0.0168 or -4.31% to $0.37 Proceeds are estimated at $25 M SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44 Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering. The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.
5 hours 9 min ago
RMi Pre-opening: Ugly
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
